Short-Term Recall and Reprocess Therapy for Post Traumatic Stress Disorder (PTSD)

Inclusion Criteria: * • Diagnosis of PTSD with a score of 25 or higher (i.e. severe PTSD) on the Clinician- Administered PTSD Scale (CAPS-5) at screening. * Subjects on FDA-approved antidepressants, trazodone, atypical neuroleptic, prazosin, or clonidine may enter the study if they have been on a stable treatment, as determined by the study clinician, for at least 4 weeks prior to randomization. Following randomization, small changes to doses may be allowable at the PI's discretion. * Able to provide written informed consent. * Able to read and write English/Hebrew. Exclusion Criteria: * • Patients with a diagnostic history of bipolar disorder, borderline personality disorder, obsessive-compulsive disorder, schizophrenia or schizoaffective disorder or currently exhibiting psychotic features as determined by the clinical interview; dementia or suspicion thereof, are excluded. Other DSM Axis I disorders are permitted as long as they are not considered primary disorders. * Patients with a history of antidepressant-induced hypomania or mania as determined by open-ended psychiatric interview. * Current, ongoing serious suicidal risk as assessed by evaluating. * Moderate severity or greater Substance Use Disorder (excepting Alcohol Use Disorder) during the 3 months prior to randomization, as determined by the SCID. * History of traumatic brain injury (TBI) with loss of consciousness for more than 24 hours or posttraumatic amnesia for more than 7 days may be considered if the trauma occurred more than 1 year ago, and no more than minimal symptoms have persisted over the past year. * Any significant history of neurological illness or heart disease. * Any signs of major medical or neurological illness on examination or as a result of ECG screening or laboratory studies. * Any history indicating learning disability or mental retardation.